BioCentury | Aug 17, 2019
Financial News

Aug. 16 Financial Quick Takes: Trio of IPO filings; plus Bellicum, Generex

...the company; other shareholders with greater than 10% stake include RA Capital, TPG Biotech and Shin Nippon Biomedical Laboratories Ltd....
BioCentury | Apr 24, 2019
Financial News

Why Satsuma investors see room for another migraine therapy

...Wellington Management led the round. Also participating were existing backers RA Capital, TPG Biotech and Shin Nippon Biomedical Laboratories Ltd....
...Osage University Partners, CAM Capital, Surveyor, Eventide Asset Management, Cormorant, Lumira Ventures and SBI Investment. Shin Nippon...
BioCentury | Jan 6, 2017
Financial News

Shin Nippon spins out Satsuma with $12M series A

...migraine. STS101 combines dihydroergotamine (DHE) with proprietary dry powder nasal formulation and delivery technologies from Shin Nippon...
...about a year. The newco’s board includes RA’s Rajeev Shah and TPG’s Heath Lukatch. Jaime De Leon Shin Nippon Biomedical Laboratories Ltd. Satsuma...
BioCentury | Jan 6, 2017
Company News

Shin Nippon Biomedical spins out Satsuma

...dihydroergotamine (DHE) delivered using technology from Shin Nippon. Shin Nippon Biomedical Laboratories Ltd. (Tokyo:2395), Tokyo, Japan Business: Neurology, Drug delivery Alicia Parker Shin Nippon Biomedical Laboratories Ltd. Satsuma...
BioCentury | Mar 23, 2015
Company News

Shin Nippon Biomedical Laboratories Ltd, ISA Pharmaceuticals deal

...ISA Pharmaceuticals’ ISA Therapeutics B.V. subsidiary partnered with Shin Nippon to combine Shin Nippon’s nasal drug delivery technology...
...for cervical cancer and anal intraepithelial neoplasia (AIN). ISA said financial terms are not disclosed. Shin Nippon Biomedical Laboratories...
BioCentury | Feb 9, 2015
Financial News

WaVe Life Sciences completes venture financing

...Venture financing Raised: $18 million Investors: RA Capital Healthcare Fund L.P.; Kagoshima Shinsangyo Sosei Investment; SNBL...
BioCentury | Feb 9, 2015
Finance

New WaVe of nucleic acids

...and Kagoshima Shinsangyo Sosei Investment, a large commercial development bank in Japan. Existing investor Shin Nippon Biomedical Laboratories (SNBL...
BioCentury | Feb 3, 2015
Financial News

WaVe closes $18M series A round

...series A round led by RA Capital Management and Kagoshima Shinsangyo Sosei Investment. Founding investor SNBL...
BioCentury | Sep 15, 2014
Company News

Shin Nippon Biomedical Laboratories, G2B deal

...G2B an option for non-exclusive rights to its uco System nasal delivery platform. Upon exercise, Shin Nippon...
...the uco System, which consists of a muco-adhesive powder drug carrier designed for use with Shin Nippon's...
...to treat anaphylaxis. G2B declined to disclose additional details, and Shin Nippon could not be reached. Shin Nippon Biomedical Laboratories Ltd....
BioCentury | Sep 15, 2014
Company News

Shin Nippon Biomedical Laboratories, Sosei deal

...non-binding letter of intent with Sosei to negotiate a deal to co-develop products based on Shin Nippon's...
...non-exclusive license to the technology platform -- brings expertise in repurposing and formulation development, while Shin Nippon...
...fund "initial project financing" for G2B011 in return for an undisclosed portion of G2B011 revenues. Shin Nippon...
Items per page:
1 - 10 of 22
BioCentury | Aug 17, 2019
Financial News

Aug. 16 Financial Quick Takes: Trio of IPO filings; plus Bellicum, Generex

...the company; other shareholders with greater than 10% stake include RA Capital, TPG Biotech and Shin Nippon Biomedical Laboratories Ltd....
BioCentury | Apr 24, 2019
Financial News

Why Satsuma investors see room for another migraine therapy

...Wellington Management led the round. Also participating were existing backers RA Capital, TPG Biotech and Shin Nippon Biomedical Laboratories Ltd....
...Osage University Partners, CAM Capital, Surveyor, Eventide Asset Management, Cormorant, Lumira Ventures and SBI Investment. Shin Nippon...
BioCentury | Jan 6, 2017
Financial News

Shin Nippon spins out Satsuma with $12M series A

...migraine. STS101 combines dihydroergotamine (DHE) with proprietary dry powder nasal formulation and delivery technologies from Shin Nippon...
...about a year. The newco’s board includes RA’s Rajeev Shah and TPG’s Heath Lukatch. Jaime De Leon Shin Nippon Biomedical Laboratories Ltd. Satsuma...
BioCentury | Jan 6, 2017
Company News

Shin Nippon Biomedical spins out Satsuma

...dihydroergotamine (DHE) delivered using technology from Shin Nippon. Shin Nippon Biomedical Laboratories Ltd. (Tokyo:2395), Tokyo, Japan Business: Neurology, Drug delivery Alicia Parker Shin Nippon Biomedical Laboratories Ltd. Satsuma...
BioCentury | Mar 23, 2015
Company News

Shin Nippon Biomedical Laboratories Ltd, ISA Pharmaceuticals deal

...ISA Pharmaceuticals’ ISA Therapeutics B.V. subsidiary partnered with Shin Nippon to combine Shin Nippon’s nasal drug delivery technology...
...for cervical cancer and anal intraepithelial neoplasia (AIN). ISA said financial terms are not disclosed. Shin Nippon Biomedical Laboratories...
BioCentury | Feb 9, 2015
Financial News

WaVe Life Sciences completes venture financing

...Venture financing Raised: $18 million Investors: RA Capital Healthcare Fund L.P.; Kagoshima Shinsangyo Sosei Investment; SNBL...
BioCentury | Feb 9, 2015
Finance

New WaVe of nucleic acids

...and Kagoshima Shinsangyo Sosei Investment, a large commercial development bank in Japan. Existing investor Shin Nippon Biomedical Laboratories (SNBL...
BioCentury | Feb 3, 2015
Financial News

WaVe closes $18M series A round

...series A round led by RA Capital Management and Kagoshima Shinsangyo Sosei Investment. Founding investor SNBL...
BioCentury | Sep 15, 2014
Company News

Shin Nippon Biomedical Laboratories, G2B deal

...G2B an option for non-exclusive rights to its uco System nasal delivery platform. Upon exercise, Shin Nippon...
...the uco System, which consists of a muco-adhesive powder drug carrier designed for use with Shin Nippon's...
...to treat anaphylaxis. G2B declined to disclose additional details, and Shin Nippon could not be reached. Shin Nippon Biomedical Laboratories Ltd....
BioCentury | Sep 15, 2014
Company News

Shin Nippon Biomedical Laboratories, Sosei deal

...non-binding letter of intent with Sosei to negotiate a deal to co-develop products based on Shin Nippon's...
...non-exclusive license to the technology platform -- brings expertise in repurposing and formulation development, while Shin Nippon...
...fund "initial project financing" for G2B011 in return for an undisclosed portion of G2B011 revenues. Shin Nippon...
Items per page:
1 - 10 of 22